Search

Now showing items 1-10 of 272

Progress in breast cancer prevention

Cuzick, J (2014-07)

Atypical Hyperplasia of the Breast

Brentnall, AR; Cuzick, J (2015-03-26)

Preventing invasive breast cancer in women at high risk based on benign/in situ pathology

Cuzick, J; Thorat, M (2015-03)

Estrogen Receptor Expression in 21-Gene Recurrence Score Predicts Increased Late Recurrence for Estrogen-Positive/HER2-Negative Breast Cancer

Dowsett, M; Sestak, I; Buus, R; Lopez-Knowles, E; Mallon, E; Howell, A; Forbes, JF; Buzdar, A; Cuzick, J (2015-06-15)

Progesterone receptor A predominance is a discriminator of benefit from endocrine therapy in the ATAC trial

Mote, PA; Gompel, A; Howe, C; Hilton, HN; Sestak, I; Cuzick, J; Dowsett, M; Hugol, D; Forgez, P; Byth, K;... (2015-06)

Use of the concordance index for predictors of censored survival data.

Brentnall, AR; Cuzick, J (2016-11-08)

The concordance index is often used to measure how well a biomarker predicts the time to an event. Estimators of the concordance index for predictors of right-censored data are reviewed, including those based on censored ...

Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy

Buus, R; Sestak, I; Kronenwett, R; Denkert, C; Dubsky, P; Krappmann, K; Scheer, M; Petry, C; Cuzick, J; Dowsett, M (2016-11)

Update on breast cancer risk prediction and prevention

Sestak, I; Cuzick, J (2015-02)

Role of quantitative p16(INK4A) mRNA assay and digital reading of p16(INK4A) immunostained sections in diagnosis of cervical intraepithelial neoplasia

Vasiljevic, N; Carter, PD; Reuter, C; Warman, R; Brentnall, AR; Carton, JR; Cuzick, J; Lorincz, AT (2017-08-15)

Population-based prevalence of cervical infection with human papillomavirus genotypes 16 and 18 and other high risk types in Tlaxcala, Mexico

Rudolph, SE; Lorincz, A; Wheeler, CM; Gravitt, P; Lazcano-Ponce, E; Torres-Ibarra, L; Leon-Maldonado, L; Ramirez, P; Rivera, B; Hernandez, R;... (2016-09-01)

1
2
3
4
. . .
28